Sage Journals: Discover world-class research

Abstract

The aim of this article is to focus on compounded bioidentical hormone (BH) formulations for menopausal symptoms and to discuss the impact of these on women's choice of treatment. The practice of compounding BHs for individualized treatment of women with menopausal symptoms has developed in the USA. In spite of claims of superiority, there is no evidence to suggest that these formulations are any more efficacious or safe than conventional hormone replacement therapy (HRT). In fact, there are some concerns about dosing inconsistencies and usefulness of saliva testing that is carried out as part of this type of treatment. While there should be no serious safety issues for women, there is a mismatch between the reality of compounded BH formulations and women's perception of them.

Keywords

bioidentical hormones menopause treatment choice

Get full access to this article

View all access options for this article.

References

Anderson

, Limacher

, Assaf

, Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33

, Simile

, Hardy

. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002;40:353–8

Hill-Sakurai

, Muller

, Thom

. Complementary and alternative medicine for the menopause: a qualitative analysis of women's decision making. J Gen Intern Med 2008;23:619–22

Seidl

, Stewart

. Alternative treatments for menopausal symptoms: qualitative study of women's experiences. Can Fam Physician 1998;44:1271–6

Adams

, Cannell

. Women's beliefs about “natural” hormones and natural hormone replacement therapy. Menopause 2001;8:433–40

See www.johnleemd.com (last checked 4 February 2011)

No authors. Compounded hormone therapies: unproven, untested- and popular. Endocrine Today. Posted 25 March 2008. See http//endocrinetoday.com (last checked 4 February 2011)

FDA Center for Drug Evaluation and Research. Report: Limited FDA survey of compounded drug products (2003). See www.fda.gov/cder/pharmcomp/survey.htm (last checked 4 February 2011).

Mahaguna

, McDermott

, Zhang

, Ochoa

. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm 2004;30:1069–78

10.

Fugh-Bergman

, Bythrow

. Bioidentical hormones for menopausal hormone therapy: variations on a theme. JGIM 2007;22:1030–34

11.

Boothby

, Doering

, Kipersztok

. Bioidentical hormone therapy: a review. Menopause 2004;11:356–67

12.

Stanczyk

, Paulson

, Roy

. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause 2005;12:232–7

13.

No authors. Bioidentical hormones. Med Lett Drug Ther 2010;52:43–4

14.

No authors. What are bioidentical hormones? Harvard Women's Health Watch, August 2006. See http://www.health.harvard.edu/women (last checked 4 February 2011)

Compounded or confused? Bioidentical hormones and menopausal health

Abstract

Keywords

Get full access to this article

References